These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39414606)

  • 1. [Efficacy and safety of venetoclax combined with decitabine, modified HA regimen and DLI in the treatment of relapsed pediatric AML/MDS after allogeneic hematopoietic stem cell transplantation].
    Zhang F; Wang HF; Hu GH; Suo P; Bai L; Wang Y; Zhang XH; Huang XJ; Cheng YF
    Zhonghua Xue Ye Xue Za Zhi; 2024 Sep; 45(9):832-837. PubMed ID: 39414606
    [No Abstract]   [Full Text] [Related]  

  • 2. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
    Short NJ; Nguyen D; Jabbour E; Senapati J; Zeng Z; Issa GC; Abbas H; Nasnas C; Qiao W; Huang X; Borthakur G; Chien K; Haddad FG; Pemmaraju N; Karrar OS; Nguyen D; Konopleva M; Kantarjian H; Ravandi F
    Lancet Haematol; 2024 Nov; 11(11):e839-e849. PubMed ID: 39303729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of gilteritinib-based combination therapy bridging allo-HSCT in relapsed or refractory acute myeloid leukemia patients with positive FLT3-ITD mutation].
    Xu Y; Zhang J; Xue SL; Miao M; Wang Y; Chen SN; Qiu HY; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):357-363. PubMed ID: 38951063
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical efficacy of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome-evolved acute myeloid leukemia].
    Chen SL; Shi YY; Zhang LN; Gong M; Zhang XY; Zhao XL; Hao MZ; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):364-369. PubMed ID: 38951064
    [No Abstract]   [Full Text] [Related]  

  • 5. Uniform Graft-versus-Host Disease Prophylaxis using Post-Transplantation Cyclophosphamide, Methotrexate, and Cyclosporine following Peripheral Blood Hematopoietic Stem Cell Transplantation from Matched and Haploidentical Donors for Transfusion-Dependent Thalassemia: A Retrospective Report from the Bone Marrow Failure Working Group of Hunan Province, China.
    Gong S; Tian X; Yang R; Yang L; Wang Z; Yang K; Chen K; He X; Deng W; Yang X; Lei M; Fu B
    Transplant Cell Ther; 2024 Dec; 30(12):1213.e1-1213.e12. PubMed ID: 39236789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant.
    LeBlanc R; Thiant S; Terra R; Ahmad I; Claveau JS; Bambace N; Bernard L; Cohen S; Delisle JS; Lachance S; Kiss T; Roy DC; Sauvageau G; Roy J
    Curr Oncol; 2024 Nov; 31(11):7258-7274. PubMed ID: 39590165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CLAG±DAC regimen in the treatment of refractory/relapsed acute myeloid leukemia].
    Hua WX; Yao WQ; Zhou M; Qi JQ; Kang HZ; Wang RJ; Cai CS; Liu YJ; Wu DP; Han Y
    Zhonghua Xue Ye Xue Za Zhi; 2024 Sep; 45(9):838-843. PubMed ID: 39414607
    [No Abstract]   [Full Text] [Related]  

  • 8. [Analysis of the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome with blastomycosis and survival comparison of different subtypes after the WHO 2022 reclassification].
    Wang H; Ma RZ; Pang AM; Yang DL; Chen X; Zhang RL; Wei JL; Ma QL; Zhai WH; He Y; Jiang EL; Han MZ; Feng SZ
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):445-452. PubMed ID: 38964918
    [No Abstract]   [Full Text] [Related]  

  • 9. Salvage hematopoietic stem cell transplantation for patients with higher leukemia burden in relapsed or refractory acute myeloid leukemia: a ten-year study.
    Jiang S; Lu X; Wei R; Zhang A; Chen H; Shi W; Xia L
    Ann Hematol; 2023 Nov; 102(11):3205-3216. PubMed ID: 37682324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDS.
    Radford M; Garcia-Horton A; Badami R; Jin E; Usmani N; Grafodatskaya D; McCready E; Khalaf D; Walker I; Leber B; Lepic K; Pond G; Berg T
    Transplant Cell Ther; 2024 Nov; ():. PubMed ID: 39547311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety analysis of venetoclax combined with hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes in the real world].
    Gao QY; Li B; Qu SQ; Pan LJ; Jiao M; Zhao JY; Xu ZF; Xiao ZJ; Qin TJ
    Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):156-162. PubMed ID: 38604792
    [No Abstract]   [Full Text] [Related]  

  • 13. Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia.
    Zhong X; Wang J; Dai Y; Huang X; Liu J; Xiang B; Ma H
    Hematology; 2024 Dec; 29(1):2433172. PubMed ID: 39585800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of venetoclax combined with hypomethylating agents in the treatment of 83 patients with higher-risk myelodysplastic syndromes].
    Liu L; He F; Xu Y; Li T; Li YF; Tang P; Sun L
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):277-283. PubMed ID: 38716600
    [No Abstract]   [Full Text] [Related]  

  • 16. [Efficacy of allogeneic hematopoietic stem cell transplantation based on a total body irradiation conditioning treatment regimen for adult acute lymphocytic leukemia].
    Xiao QQ; Yu XL; Song XC; Hou YX; Deng L; Li WJ; Zhou F
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):249-256. PubMed ID: 38716596
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation.
    Nozzoli C; Pucillo M; Giaccone L; Rambaldi A; Stanghellini MTL; Benedetti E; Russo D; Mordini N; Mangiacavalli S; Bernasconi P; Parma M; Carluccio P; Galieni P; Rivela P; Martino M; Chiusolo P; Isola M; De Martino M; Oldani E; Degrandi E; Boncompagni R; Antonioli E; Carnevale F; Tozzi M; Selleri C; Fanin R; Patriarca F;
    Transplant Cell Ther; 2024 Nov; ():. PubMed ID: 39505212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a Modified Post-Transplant Cyclophosphamide Regimen for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Severe Aplastic Anemia: A Prospective Study.
    Chen X; Chen C; Zhou M; Zhang Y; Wang C; Li Y; Zhou R; Xu S; Zhou W; Deng T; Pan S; Wu L; Zhang Y; Mo W; Wang S
    Transplant Cell Ther; 2024 Nov; 30(11):1099.e1-1099.e10. PubMed ID: 39187160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial.
    Kwiatkowski JL; Walters MC; Hongeng S; Yannaki E; Kulozik AE; Kunz JB; Sauer MG; Thrasher AJ; Thuret I; Lal A; Tao G; Ali S; Thakar HL; Elliot H; Lodaya A; Lee J; Colvin RA; Locatelli F; Thompson AA
    Lancet; 2024 Nov; 404(10468):2175-2186. PubMed ID: 39527960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.